NCE-1 Intelligence & Market Opportunity

Qulipta

Atogepant

Antimigraine

Oral Tablet

Approval Date

28-Sep-21

NCE-1 Date

28-Sep-25

NCE Date

28-Sep-26

Commercial snapshot

Market performance & projections

Revenue ($M)

1036

CAGR (%)

0.1554

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1336

2027

1510

2028

1693

2029

1846

2030

1994

2031

2061

2032

1967

Molecule profile

Details & specifications

Molecule

Atogepant

Innovator

ABBVIE INC.

Dosage Form

Oral Tablet

Strength

30 mg, 60 mg, 10 mg

Therapeutic Category

Antimigraine

Usage

To prevent episodic migraines Drug Trial Snapshot

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.